Slides TAT 2011

On this page, you may download a PDF version of presentations given at TAT 2011 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Just click on the session titles below to jump directly to the presentations available for each session. Below, only the presenting authors names are shown. For the full list of authors we refer to the abstract section. Posters presented at TAT 2011 are not available online.

Monday, March 7

Plenary session 1: Opening ceremony

Plenary session 2: Targeting mutated BRAF and KRAS

Plenary session 3: Miscellaneous drugs and targets (1)

Plenary session 4: Refining anti-angiogenic therapy: Getting over the wall

Tuesday, March 8

Plenary session 5: Targeting DNA damage repair beyond PARP

Plenary session 6: Hsp90 inhibitors

Plenary session 7: Metabolic targets

Plenary session 8: Targeting the androgen axis and other targets in prostate cancer

Wednesday, March 9

Plenary session 9: Methodological and regulatory issues in development of targeted agents

Plenary session 10: Immunological targets

Plenary session 11: Drugs targeting the PI3K-Akt-mTOR pathway

Plenary session 12: Miscellaneous drugs and targets (2)

Plenary session 13: Roles for genome sequencing in drug development

Plenary session 1: Opening ceremony

KL1. NDDO Honorary Award Lecture 2011: The changing landscape of lung cancer and its treatment. Giuseppe Giaccone, Bethesda, MD, USA.

KL2. Keynote Lecture: Synthetic lethality in cancer treatment: Current status of PARP inhibitors. A. Hilary Calvert, London, UK.

KL3. Keynote Lecture: Bridging the gap to utilizing whole genome data in drug development. Andrew Futreal, Hinxton, UK.

Plenary session 2: Targeting mutated BRAF and KRAS

IL01. Educational lecture: Targeting the Ras-Raf pathway for cancer therapy. Ji Luo, Bethesda, MD, USA.

IL02. Response and resistance to BRAF inhibitors in melanoma. Keith Flaherty, Boston, MA, USA.

IL03. KRAS mutations in human tumors. Massimo Broggini, Milan, Italy.

Plenary session 3: Miscellaneous drugs and targets (1)

PP01. Phase II/pharmacodynamic trial of PD0332991 in patients with Kras mutant colorectal cancer. P.J. O'Dwyer, R. Perini, A. DeMichele, D. Vaughn, W. Sun, B. Giantonio, U. Teitelbaum, S. Randolph, J. Christensen, D. Pryma, C. Divgi. (slides not available)

PP02. Pooled analysis of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) following prior systemic therapy. S. Bates, F. Foss, R. Piekarz, S. Horwitz, B. Pro, M. Prince, L. Sokol, M. Greenwood, D. Caballero, P.Borchmann, F. Morschhauser, M. Wilhelm, L. Pinter-Brown, S.Padmanabhan, A. Shustov, J. Wright, M. Kirschbaum,J. Zain, S.L. Allen, E.S. Jaffe, J. Nichols, J. Wolfson, J. Balser, B. Coiffier.

PP03. Sym004: A novel synergistic anti-EGFR antibody mixture with superior anti-cancer efficacy. R. Dienstmann, A. Patnaik, A.W. Tolcher, M.W. Pedersen, H.J. Jacobsen, K. Kofoed, J. Petersen, J. Tabernero, M. Kragh.

PP04. Definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents. C. Le Tourneau, R.A. Razak, H.K. Gan, S. Pop, X. Paoletti.

Plenary session 4: Refining anti-angiogenic therapy: Getting over the wall

IL04. Educational lecture: Overview of current strategies and results. Lee Ellis, Houston, TX, USA.

IL05. Strategies to complement VEGF targeted therapies. Amy Peterson, San Francisco, CA, USA.

IL06. Targeting acquired resistance to angiogenesis inhibitors by targeting HIF-1. Giovanni Melillo, Frederick, MD, USA.

IL07. Fibroblast growth factors: New drugs to manage a morpheic tumor target. Filippo de Braud, Milan, Italy.

IL08. Is the tumor genome helping us to better select patients for anti-angiogenic therapy? Emile Voest, Utrecht, The Netherlands.

Plenary session 5: Targeting DNA damage repair beyond PARP

IL09. PARP as a novel therapeutic target in cancer. Christina Annunziata, Bethesda, MD, USA.

IL10. Chk inhibitors for the treatment of human malignancies. Adrian Senderowicz, Wilmington, DE, USA.

IL11. Targeting DNA damage repair beyond PARP - further drugs or targets in development. Ruth Plummer, Newcastle, UK.

PP05. Preclinical characterization of ARRY-575: a potent, selective, and orally bio-available small molecule inhibitor of Chk1. M.J. Humphries, I. von Carlowitz, Y.L. Le Huerou, N. Randolph, I. Gunawardana, P.J. Mohr, B. Wang, M.A. Lyon, M. Chicarelli, F. Sullivan, J.F. Blake, S.L. Winski, E. Wallace.

PP06. Namitecan (ST 1968), a novel camptothecin analogue. C. Sessa, D. Hess, A. Fasolo, R. Calderone, S. Bastian, G. Del Conte, S. De Dosso, N. Hagner, L. Luraghi, S. Pace, N. Coceani, E. Maccioni, L. Gianni.

Plenary session 6: Hsp90 inhibitors

IL12. Educational lecture: Targeting the molecular chaperone Hsp90 for cancer therapy: What does the biology tell us? Leonard Neckers, Bethesda, MD, USA.

IL13. Heat shock protein 90 (Hsp90) inhibition as a potential novel approach to the treatment of patients with ALK mutated non-small cell lung cancer (NSCLC). Robert Ross, Cambridge, MA, USA.

IL14. Discovery and development of AUY922. Udai Banerji, Sutton, Surrey, UK.

IL15. Hsp90 inhibitors in clinical development: AT13387. Geoffrey Shapiro, Boston, MA, USA.

IL16. Hsp90 inhibitors in clinical development: STA-9090 (Ganetespib). Geoffrey Shapiro, Boston, MA, USA.

Plenary session 7: Metabolic targets

IL17. Educational lecture: Metabolic targeting: an update on biguanides. Michael Pollak, Montreal, Canada. (slides not available)

IL18.Targeting metabolism: Metformin in cancer prevention and therapy. Marco Pierotti, Milan, Italy.

IL19. Cancer metabolism: Drug discovery to control critical metabolic enzymes. David Schenkein, Cambridge, MA, USA. (slides not available)

IL20. Putting cancer on a diet: Targeting glycolysis and fatty acid metabolism as therapeutic strategies. Perry Nisen, King of Prussia, PA, USA. (slides not available)

Plenary session 8: Targeting the androgen axis and other targets in prostate cancer

IL21. Educational lecture: New targets and drugs in prostate cancer. Cora Sternberg, Rome, Italy.

IL22. Improving outcome from advanced prostate cancer through rational drug development. Johann de Bono, Sutton, Surrey, UK.

IL24. Tubulin-binding drugs in prostate cancer. Christophe Massard, Villejuif, France.

Plenary session 9: Methodological and regulatory issues in the development of targeted agents

IL25. Report of MDICT Task Force Meeting 2011. A. Hilary Calvert, London, UK

IL26. “What went wrong with aurora kinase inhibitors?” Tito Fojo, Bethesda, MD, USA.

IL27. “What went wrong with IGF-1R inhibitors?” Michael Pollak, Montreal, Canada. (slides not available)

IL28. Targeting from a regulatory perspective. Bertil Jonsson, Stockholm, Sweden.

Plenary session 10: Immunological targets

IL29. Immunological targets: Basic aspects. Ignacio Melero, Navarra, Spain.

IL30. It’s a new world in melanoma. Alexander M.M. Eggermont, Villejuif, Paris, France. (slides not available)

PP07. Novel strategies in the design and development of recombinant vaccines for cancer therapy. R.A. Madan, C. Palena, J.L. Gulley, J.W. Hodge, K.Y. Tsang, J.W. Greiner, J. Huang, J. Schlom. (slides not available)

Plenary session 11: Drugs targeting the PI3K – Akt – mTOR pathway

IL31. Educational lecture: The PI3K/Akt/mTOR signaling pathway. Philip Dennis, Bethesda, MD, USA.

IL32. New drugs targeting the PI3K/Akt/mTOR pathway. Patricia LoRusso, Detroit, MI, USA.

IL33. Targeting the PI3K-Akt-mTOR pathway with GDC-0068, a novel selective ATP competitive Akt inhibitor. Josep Tabernero, Barcelona, Spain.

Plenary session 12: Miscellaneous drugs and targets (2)

IL36. SMAC mimetics as new anticancer agents. Alex Adjei, Buffalo, NY, USA.

IL34. PTEN loss induced cellular senescence for “pro-senescence” therapy for cancer. Andrea Alimonti, Bellinzona, Switzerland.

IL35. Discovery and development of next generation epigenetic DNMT inhibitors: Development of SGI-110, a novel DNMT inhibitor. Jean-Pierre Issa, Houston, TX, USA.

PP08. HERG1 channels: from antitargets to novel therapeutic targets in oncology. A. Arcangeli, A. Becchetti, O. Crociani, M. D’Amico, L. Gasparoli, M. Masselli, S. Pillozzi, K. Mugridge,W. Tiedke.

PP09. Potent inhibition of multiple proteasome subunits by carfilzomib in solid tumor and multiple myeloma patients. S.J. Lee, T.M. Woo, M. Vallone, S. Arastu-Kapur, E.T. Chan, A.F. Wong, M.H. Le, A.L. Hannah, C.J. Kirk.

PP10. Preliminary experience of a phase I clinical trial combining an antiviral approach to chemoradiotherapy for HPV related malignancies. E. Deutsch, C. Haie-Meder, C. Bourgier, M.C. Vozenin, C. Lhomme, J. Bourhis, J.C. Soria (slides not available)

Plenary session 13: Roles for genome sequencing in drug development

IL37. Implications of the new sequencing technologies for clinical oncology. Paul Meltzer, Bethesda, MD, USA.

IL38. An integrated and comprehensive approach of functional and structural genomics at the era of exome and next generation sequencing in early drug development. Vladimir Lazar, Villejuif, Paris, France.